Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care
A Clinical Study of Reprise Biomedical's Miro3D Wound Matrix in the Outpatient Management of Wounds and Ulcerations
Reprise Biomedical, Inc.
20 participants
Feb 29, 2024
INTERVENTIONAL
Conditions
Summary
This clinical study is being conducted to evaluate how well the Miro3D Wound Matrix helps heal difficult wounds and ulcerations in an outpatient care setting. Miro3D is a biologic wound dressing made from porcine (pig) liver tissue. It is processed to remove all cells, creating a clean scaffold that can support the body's natural healing process. The goal of this study is to see how effective Miro3D is when used alongside standard wound care for helping wounds close and reducing pain and discomfort. The study is designed as a post-market, proof-of-concept trial, meaning the product is already commercially available, and researchers are evaluating how it works in real-world clinical settings. A total of up to 20 adult participants will be enrolled. Participants may have wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers, or surgical wound dehiscence. These wounds may be complex in nature, including tunneling or undermining, which often makes them more difficult to treat. Participants will receive standard wound care along with weekly Miro3D applications for the first 4 weeks. If the wound is not fully healed after 4 weeks, Miro3D will then be applied every 2 weeks until healing is achieved or up to 12 weeks total. Throughout the study, participants will return weekly for wound assessments and to complete brief questionnaires about their pain levels and quality of life. The main goals of the study are: 1. To measure how much the wound size shrinks (known as percent area reduction or PAR). 2. To evaluate how much healthy granulation tissue (new tissue) forms in the wound. 3. To compare healing outcomes when Miro3D is used weekly versus every two weeks. 4. To understand how the treatment affects patients' quality of life, including pain, mobility, and emotional wellbeing. Each participant will be closely monitored by the clinical team throughout the 12-week study period. If a wound heals earlier, the participant will finish the study at that time. If the wound does not heal, the participant may return to their regular physician for follow-up care.
Eligibility
Inclusion Criteria10
- Age 18 or older and able to provide informed consent.
- Has an open wound or ulceration, preferably with tunneling or undermining.
- If multiple wounds/ulcerations are present, only one will be selected for Miro3D treatment.
- Other wounds must be ≥2 cm away from the study wound.
- Wound should be debrided with a clinical goal of healing, even if some infection remains.
- Previous infections must be adequately treated and controlled (per IDSA guidelines).
- Willing and able to comply with offloading and/or compression requirements.
- Must have a stable living environment for wound care adherence.
- Study wound must have a clean base free of devitalized tissue or debris at the time of Miro3D placement.
- Provides consent for digital photo documentation.
Exclusion Criteria12
- Active, untreated osteomyelitis.
- Malignancy or vasculitis at the wound site.
- Undergoing chemotherapy.
- On dialysis.
- Use of investigational drugs or therapies within 30 days before screening.
- Conditions that significantly impair study adherence or known history of medical non-compliance.
- Known sensitivity to porcine materials.
- Third-degree burns.
- Worsening ischemia or gangrene at screening.
- Prior radiation to the study wound site.
- Exposed hardware, implants, or fixation devices in the study wound.
- Receiving palliative or comfort care.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This intervention is a sterile, acellular, three-dimensional biologic scaffold derived from porcine liver tissue using a proprietary perfusion decellularization and drying process. It retains the native extracellular matrix structure and supports tissue granulation and healing in complex wounds. Miro3D is applied topically to the debrided wound bed and rehydrated prior to use. It is indicated for use in a range of chronic and complex wounds, including diabetic foot ulcers, venous leg ulcers, pressure injuries, and surgical dehiscence. In this study, it is administered in an outpatient setting alongside standard of care treatments.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06939673